Pancreatic Cancer Early Detection Consortium
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct
research on multiple aspects of early detection and prevention of pancreatic ductal
adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history
...
Age: 18 - 90 years
Gender: All
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer
This phase I/II trial studies the side effects and best dose of M3814 and to see how well it
works when given together with radiation therapy in treating patients with pancreatic cancer
that cannot be removed by surgery and has not spread to other parts of the body ...
Age: 18 years - 66+
Gender: All
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
This randomized phase III trial studies cabozantinib to see how well it works compared with
placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to
other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a t...
Age: 18 years - 66+
Gender: All
Celiac Plexus Radio-Surgery for Pain Management
Many cancer patients, especially those with pancreatic cancer, suffer from severe lower back / upper abdominal pain. This pain is often poorly managed with standard treatments; the doses of painkiller required often induce side effects, whereas nerve block procedures (w...
Age: 18 years - 66+
Gender: All
Pancreas Registry and High Risk Registry
The purpose of this study is to establish a registry of patients with pancreatic diseases.
Patients included in the registry may include those with: pancreatic cancer, precancerous
lesions of the pancreas, inflammatory lesions of the pancreas, cystic lesions of the
...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Ge...
Age: 18 years - 66+
Gender: All
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: - ORR at 6 month...
Age: 18 years - 66+
Gender: All
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: - ORR at 6 month...
Age: 18 years - 66+
Gender: All